Updated molecular testing guideline strongly recommends ROS1 testing for NSCLC

An 2018 update to the lung cancer molecular testing guideline says testing for ROS1 rearrangements is strongly recommended for all lung cancer patients regardless of clinical characteristics.

The article “Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors” was published online January 23, 2018, in the Journal of Molecular Diagnostics by a partnership of three organizations:

  • College of American Pathologists (CAP)
  • International Association for the Study of Lung Cancer (IASLC)
  • Association for Molecular Pathology (AMP)

REFERENCES:

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors (Journal of Molecular Diagnostics)

AMP article about the updated guideline